I do remember them saying that there were some differences between treating different indications, but nothing substantial. Earlier this year, they started reclassifying based on indication. Yescarta for NHL is KTE-C19. Unapproved indications are KTE-X19 and upon approval will receive a KTE-_19 designation. Makes sense to separate products by indication since they have varying efficacies. Zuma-18 expansion for MCL is exactly what they did with Zuma-9. Separate the FDA submission data from ongoing trials. So MCL is likely next approval.
They have filed trademarks on a bunch of bad names in the last year. However, their "Dismantle Cell" marketing phrase is a clever take on Mantle Cell Lymphoma.
Here's their listings. I always thought Tucarti was a decent name. Your Car-T. Instead, the marketing is "Say YES to..."
I like the idea of split dosing, but more as a potential booster. Better solutions with lower CRS/hospitalization will come. Persistence is clearly a major component of sustaining efficacy.